Skip to Content

'
Jennifer Keating Litton, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Research Interests

Pregnancy and breast cancer.

Genetic testing.

Molecular changes of breast cancer genes.

Education & Training

Degree-Granting Education

2000 University of Massachusetts Medical School, Worcester, MA, MD, Medicine
1992 Duke University, Durham, NC, AB, History and English

Postgraduate Training

12/2004-12/2006 Clinical Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX
7/2003-6/2004 Chief Resident, Baylor College of Medicine, Houston, TX
7/2001-6/2003 Clinical Residency, Baylor College of Medicine, Houston, TX
6/2000-6/2001 Clinical Internship, Baylor College of Medicine, Houston, TX

Board Certifications

11/2007 Medical Oncology
8/2003 ABIM

Experience/Service

Administrative Appointments/Responsibilities

Director of Breast Medical Oncology Education Program, University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/2013-present

Other Appointments/Responsibilities

PDQ Cancer Genetics Editorial Board Member, National Institute of Health, Bethesda, MD, 6/2015-present
Advisory Board, LBBC, Houston, TX, 2/2013-present
Guideline Panel Member Genetic/Familial High Risk Assessment: Breast and Ovarian Panel, National Comprehensive Cancer Network, Fort Washington, PA, 1/2008-present

Consultantships

Consultant, BioMarin, Houston, TX, 2014-present
Consultant, Novartis, Houston, TX, 2014-present

Institutional Committee Activities

Member, Division of Radiation Oncology Chair Search, 2/2014-6/2014
Member, Heart of Leadership Program, 9/2013-2/2014
Member, Division of Cancer Medicine Fellowship Steering Committee, 6/2013-present
Director, Rotating Trainees, Post-Doctoral Fellows and Observers Program, 2/2013-present
Faculty Member, Hematology/Oncology Fellowship Steering Committee, 1/2013-present
Member, Institutional Guidelines on Breast Cancer, 2013-present
Member, Institutional Guidelines on Pregnancy Testing, 2013-present
Member, Clinical Competency Committee, 2013-present
Member, Plastic Surgery Chair Search, 8/2012-4/2013
Member, Faculty Senate, 2012-present
Member, Pregnancy Algorithm Committee, 2011-present
Member, Institutional Guidelines on Fertility Preservation Committee, 2010-present
Member, Clinical Research Committee 3, 2007-present

Professional Memberships

Suites of Hope, Houston, TX
Board Member, 1/2012-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Sanford RA, Song J, Gutierrez Barrera AM, Profato JL, Woodson AH, Litton J, Bedrosian I, Albarracin C, Valero V, Arun BK. High incidence of germline BRCA mutation in patients with ER low positive/PR low positive/HER-2 neu negative tumors. Cancer. In Press.
2. Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam F. Phase II randomized study of ixabepilone vs. observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2-negative breast cancer. Clinical Breast Cancer. In Press.
3. Arun BK, Gutierrez Barrera AM, Profato JL, Lin H, Litton J, Tripathy D, Kuerer HM, Ardic C. Predictors that influence election of contralateral prophylactic mastectomy among women with ductal carcinoma in situ who are BRCA-negative. J of Can. In Press.
4. Bayraktar S, Jackson M, Gutierrez Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Arun BK. Genotype-phenotype correlations by ethnicity and mutation location in BRCA mutation carriers. Breast J 21(3):260-7, 5/2015. PMID: 25789811.
5. De Lu, F. Eckhardt B, Lim B, Moulder S, Litton J, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget, 5/2015. e-Pub 5/2015. PMID: 25973541.
6. Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer 15(2):153-60, 4/2015. PMID: 25454687.
7. Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Association of body mass index changes during neoadjuvant chemotherapy with pathologic complete response and clinical outcomes in patients with locally advanced breast cancer. J Cancer 6(4):310-8, 1/2015. PMCID: PMC4349870.
8. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121(2):269-75, 1/2015. e-Pub 9/2014. PMCID: PMC4293332.
9. Woodson AH, Muse KI, Lin H, Jackson M, Mattair DN, Schover L, Woodard T, McKenzie L, Theriault RL, Hortobágyi GN, Arun B, Peterson SK, Profato J, Litton JK. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist 19(8):797-804, 8/2014. e-Pub 6/2014. PMCID: PMC4122483.
10. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. Ann Oncology 25(6):1122-7, 6/2014. PMCID: PMC4037860.
11. Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG; the Northwestern Cancer Genetics Group. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer 120(10):1557-64, 5/2014. PMID: 24522996.
12. Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors that Influence contralateral prophylactic mastectomy election among women with ductal carcinoma In situ who were evaluated for BRCA genetic testing. Ann Surg Oncol, 5/2014. e-Pub 2014. PMID: 24796968.
13. Morrow PK, Broxson AC, Munsell MF, Basen-Enquist K, Rosenblum CK, Schover L, Nguyen LH, Hsu L, Castillo L, Hahn KM, Litton JK, Mattair DM, Hortobagyi GN. Effect of age and race upon quality of young breast cancer survivors. Clin Breast Cancer 14(2):e 21-31, April 2014, 4/2014. e-Pub 2013. PMID: 24461458.
14. André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. e-Pub 4/2014. PMID: 24742739.
15. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4), 2014. e-Pub 4/2014. PMCID: PMCPMC4000553.
16. Weksberg DC, Allen PK, Hoffman KE, Litton JK, Strom EA, Shah RR, Kuerer HM, Hunt KK, Buchholz TA, Mittendorf EA. Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol 20(11):3430-7, 10/2013. PMID: 23720073.
17. Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol 24(10):2534-42, 10/2013. PMCID: PMC3784330.
18. Rich TA, Liu M, Etzel CJ, Bannon SA, Mork ME, Ready K, Saraiya DS, Grubbs EG, Perrier ND, Lu ND, Lu KH, Arun BK, Woodard TL, Schover LR, Litton JK. Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer 13(2):291-9, 9/2013. PMCID: PMC4159051.
19. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E. Reduction of cancer-related fatigue with dexamethasone: A double-blind, randomized, placebo-controlled trial in advanced cancer patients. J Clin Oncol 31(25):3076-82, 9/2013. e-Pub 7/2013. PMID: 23897970.
20. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-MacGregor M. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer 4(7):549-56, 8/2013. PMCID: PMC3753529.
21. Woodson AH, Profarto JL, Muse KI, Litton JK. Breast cancer in the young: role of the geneticist. J Thorac Dis 5(Suppl 1):S19-26, 6/2013. PMCID: PMC3695544.
22. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK. Genotype in BRCA-associated breast cancers. Breast J 19(1):87-91, 1/2013. e-Pub 12/2012. PMID: 23231005.
23. Bayraktar S, Gutierrez Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J 19(1):10-7, 1/2013. PMCID: PMC3568679.
24. Litton JK, Warneke CL. Hahn KM, Palla SL, Kuerer HM, Perkins GH, Mittendorf EA, Barnett C, Gonzalez-Angulo AM, Hortobagyi GN, Theriault RL. Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with non-pregnant breast cancer patients. Oncologist 18(4):369-76, 2013. PMCID: PMCPMC3639522.
25. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. J Clin Exp Mets 30(5):631-42, 2013. PMCID: PMC3857726.
26. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 24(8):1999-2004, 2013. PMCID: PMC3718505.
27. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer 12(5):364-72, 10/2012. PMID: 23040004.
28. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer 118(19):4652-9, 10/2012. e-Pub 2/2012. PMCID: PMC3910255.
29. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 133(3):1131-41, 6/2012. PMCID: PMC3855009.
30. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14(3):R83, 5/2012. PMCID: PMC3446346.
31. Bayraktar S, Hernandez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118(5):1202-11, 3/2012. PMCID: PMC3207034.
32. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton JK, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 3/2012. e-Pub 8/2011. PMID: 22009639.
33. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908-13, 2/2012. PMCID: PMCPMC3527897.
34. Chavez-MacGregor M, Brown E, Lei X, Litton JK, Meric-Bernstram F, Mittendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to taxane and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 118(2):326-32, 1/2012. PMCID: PMCPMC3158806.
35. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118(2):321-5, 1/2012. PMCID: PMC4369377.
36. Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, Palla SL, Brewster A, Bruera E. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. The Oncologist 17(10):1240-5, 2012. PMCID: PMCPMC3481889.
37. Ready K, Arun BK, Schmeler KM, Uyei A, Litton JK, Lu KH, Sun CC, Peterson SK. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer 10(4):673-9, 12/2011. PMID: 21681553.
38. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-53, 11/2011. PMCID: PMC4334122.
39. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 11(5):325-31, 10/2011. PMCID: PMC4104010.
40. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and non-carriers: a single institution experience. J Clin Oncol 29(28):3739-46, 10/2011. PMID: 21900106.
41. Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, Wagner J, Hunt KK, Woodward WA, Meric-Bernstam F. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol 18(11):3164-73, 10/2011. PMCID: PMC4337779.
42. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 117(17):3900-7, 9/2011. PMID: 21365619.
43. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol 18(9):2407-12, 9/2011. PMCID: PMC4332388.
44. Sharma R, Rourke LL, Kronowitz SJ, Oh JL, Lucci A, Litton JK, Robb GL, Babiera GV, Mittendorf EA, Hunt KK, Kuerer HM. Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg 127(5):1763-72, 5/2011. PMID: 21532405.
45. Chen JQ, Bao Y, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Katz RL, Sahin A, Bondy M, Murray JL, Radvanyi L. Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer. Horm Cancer 2(2):132-43, 4/2011. PMID: 21761336.
46. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-9, 3/2011. PMCID: PMC3048924.
47. Valero V 3rd, Kong AL, Hunt KK, Yi M, Hwang RF, Meric-Bernstam F, Bedrosian I, Ross MI, Babiera GV, Litton JK, Mittendorf EA. Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer 10(6):477-82, 12/2010. PMID: 21147692.
48. Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, Pusztai L. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116(22):5161-7, 11/2010. PMID: 20665886.
49. Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer 116(17):4168-77, 9/2010. PMCID: PMC2954673.
50. Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res 3(8):1026-34, 8/2010. PMCID: PMC4340054.
51. Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 8(5):562-94, 5/2010. PMID: 20495085.
52. Ready K, Litton JK, Arun BK. Clinical application of breast cancer risk assessment models. Future Oncol 6(3):355-65, 3/2010. PMID: 20222793.
53. Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin A, Le-Petross H, Oh J, Litton J, Hwang RF, Mittendorf EA. Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma. Clin Breast Cancer 10(1):52-8, 2/2010. PMID: 20133259.
54. Chen JQ, Litton J, Xiao L, Zhang H-Z, Warneke CL, Wu, Y, Shen X, Wu S, Sahin A, Katz R, Bondy M, Hortobagyi GN, Berinstein NL, Murray JL, Radvanyi L. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. Horm Cancer 1(1):21-33, 2/2010. PMID: 21761348.
55. Litton JK, Theriault RL. Breast cancer and pregnancy: current concepts in diagnosis and treatment. Oncologist 15(12):1238-47, 2010. PMCID: PMC3227919.
56. Dominici LS, Kuerer HM, Babiera G, Hahn KM, Perkins G, Middleton L, Ramirez MM, Yang W, Hortobagyi GN, Theriault RL, Litton JK. Wound complications from surgery in pregnancy-associated breast cancer (PABC). Breast Dis 31(1):1-5, 2010. PMID: 20519803.
57. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27(34):5700-6, 12/2009. PMCID: PMC2792998.
58. Litton JK, Theriault RL, Gonzalez-Angulo AM. Breast cancer diagnosis during pregnancy. Women's Health (Lond Engl) 5(3):243-9, 5/2009. PMCID: PMC2753540.
59. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 4/2009. PMCID: PMC2680417.
60. Beadle BM, Woodward WA, Tucker SL, Outlaw ED, Allen PK, Oh JL, Strom EA, Perkins GH, Tereffe W, Yu TK, Meric-Bernstam F, Litton JK, Buchholz TA. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys 73(3):734-44, 3/2009. PMCID: PMC3041273.
61. Beadle BM, Woodward WA, Middleton LP, Tereffe W, Strom EA, Litton JK, Meric-Bernstam F, Theriault RL, Buchholz TA, Perkins GH. The impact of pregnancy on breast cancer outcomes in women </=35 years. Cancer 115(6):1174-84, 3/2009. PMCID: PMC3063387.
62. Eralp Y, Smith TL, Altundag K, Kau SW, Litton JK, Valero V, Buzdar A, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol 135(1):141-8, 1/2009. PMID: 18581139.
63. Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26(25):4072-7, 9/2008. PMID: 18757321.
64. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B. Multifocal breast cancer in women < or =35 years old. Cancer 110(7):1445-50, 10/2007. PMID: 17676585.
65. Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, Hayes DF. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J Clin Oncol 17(5):1435-41, 5/1999. PMID: 10334528.
66. Shapiro CL, Keating J, Angell JE, Janicek M, Gelman R, Hayes D, LeBoff MS. Monitoring therapeutic response in skeletal metastases using dual-energy X-ray absorptiometry: a prospective feasibility study in breast cancer patients. Cancer Invest 17(8):566-74, 1999. PMID: 10592763.
67. Shapiro CL, Ayash L, Webb IJ, Gelman R, Keating J, Williams L, Demetri G, Clark P, Elias A, Duggan D, Hayes D, Hurd D, Henderson IC. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol 15(2):674-83, 2/1997. PMID: 9053493.

Invited Articles

1. Rich TA, Woodson AH, Litton J, Arun B. Hereditary breast cancer syndromes and genetic testing. J Surg Oncol 111(1):66-80, 1/2015. PMID: 25381882.

Editorials

1. Woodard TL, Litton JK. Fertility preservation in women with breast cancer: challenges and opportunities. Oncology (Williston Park) 27(6):544, 546, 2013. PMID: 23909068.
2. Litton JK, Gonzalez-Angulo AM. Evaluating breast cancer risk with genome-wide association studies: is this approach patient ready? J Clin Oncol 30(35):4288-9, 2012, 10/2012. PMID: 23109691.

Abstracts

1. Vila J, Bassett RL, Mittendorf EA, Bedrosian I, Shaitelman SF, Stauder MC, Chavez-Mac Gregor M, Litton JK, Yang WT, Huo L, Kuerer HM, Hunt K, Caudle AS. A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast patients. 2015 ASCO Annual Meeting (#1034), 2015.
2. Litton JK, Blum JL, Im Y-H, Martin M, Mina LA, Roche HH, Rugo HS, Visco F, Zhang C, Lokker NA, Lounsbury DL, Eiermann W. A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA). 2015 ASCO Annual Meeting (#TPS1107), 2015.
3. Fujii T, Kogawa T, Wei C, Fouad TM, Harano K, Park YS, Lim B, Tripathy D, Ueno NT, Litton JK. Association of body mass index with survival outcome in three breast cancer subtypes. 2015 ASCO Annual Meeting, 2015.
4. Basho RK, Gagliato DD, Ueno NT, Alvarez RH, Wathoo C, Chen H, Wei C, Sahin AA, Roy-Chowdhuri S, Moulder SL, Chavez-Mac Gregor M, Litton JK, Valero V, Luthra R, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. 2015 ASCO Annual Meeting (#1524), 2015.
5. Ardic C, Gutierrez-Barrera AM, Elsayegh N, Song J, Profato J, Litton JK, Giordano SH, Tripathy D, Arun B. Predictors of BRCA mutation in male breast cancer. 2015 ASCO Annual Meeting (#1538), 2015.
6. Meric-Bernstam F, Brusco L, Daniels MS, Strong LC, Shaw KR, Lu, KH, QU Y,Lara-Guerra H, Litton JK, Zhao H, Eterovic AK, Arun B, Routbort M, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. 2015 ASCO Annual Meeting (#1510), 2015.
7. Moulder SL, Ueno NT, Yang WT, Ensor J, Valero V, Litton JK, Murthy RK, Ibrahim NK, Arun B, Mittendorf EA, Hunt K, Meric-Bernstam F, Thompson AM, Piwnica-Worms H, Tripathy D, Symmans WF. Women’s triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (NACT). 2015 ASCO Annual Meeting, 2015.
8. Kogawa T, Fouad TM, Wei C, El-Zein RA, Masuda H, Chavez-Mac-Gregor M, Melhem-Bertrandt A, Litton JK, Brewster AM, Alvarez RH, Hortobagyi GN, Vicente V, Ueno NT, Theriault RL. Association between body mass index change during neoadjuvant chemotherapy and pathologic complete response and overall survival in patients with inflammatory breast cancer or locally advanced non-inflammatory breast cancer. 2014 CTRC-AACR San Antonio Breast Cancer Symposium (#PD2-4), 12/2014.
9. IIsaacs C, Ozguroglu M, Jerusalem G, Xu B, Láng I, O'Regan R, White M, Fasolo A, Litton J, Toi M, Shen K, Andre F, Vuylsteke P, Zhang Y, Zhang J, Taran T, Wilks S. BOLERO-3: Quality-of-life maintained in patients with metastatic breast cancer treated with everolimus plus trastuzumab plus vinorelbine. 2014 CTRC-AACR San Antonio Breast Cancer Symposium (#P4-12-18), 12/2014.
10. Elsayegh N, Gutierrez-Barrera A, Baum G, Muse K, Jackson M, Woodson A, Jessica P, Kuerer H, Litton J, Arun B. Factors associated with prophylactic mastectomy among BRCA-positive patients with no personal history of breast cancer. 2014 CTRC-AACR San Antonio Breast Cancer Symposium (#P5-13-03), 12/2014.
11. Rugo HS, Chambers MS, Litton J, Mayer I, Rogerio J, Demars L, Geronimo J, Warsi G, Meiller TF. Phase 2, single arm study of a steroid-based mouthwash to prevent stomatitis in women with hormone receptor–positive advanced breast cancer treated with everolimus plus exemestane. 2014 CTRC-AACR San Antonio Breast Cancer Symposium (#OT2-6-14), 12/2014.
12. Chavez-Mac Gregor M, Lei X, Litton JK, Melhem-Bertrand A, Giordano SH, Masuda H, Ueno N, Gabriel HN, Valero V. Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy. 2014 CTRC-AACR San Antonio Breast Cancer Symposium (#P3-12-06), 12/2014.
13. Murthy RK, Schover LR, Theriault RL, Valero V, Woodard TL, Hodge S, Litton JK. Women with pregnancy-associated early breast cancer achieve improved emotional well-being as a result of their cancer experience. 2014 CTRC-AACR San Antonio Breast Cancer Symposium (#P3-11-02), 12/2014.
14. Sanford RA, Song J, Gutierrez-Barrera AM, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B; The University of Texas MD Anderson Cancer Center, Houston, TX. Incidence of germline BRCA mutation in patients with ER-low positive/PR negative/HER-2 neu negative tumors. 2014 ASCO Breast Cancer Symposium, 9/2014.
15. Sanford RA, Song J, Gutierrez-Barrera AM, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B; The University of Texas MD Anderson Cancer Center, Houston, TX. Incidence of germline BRCA mutation in patients with ER-low positive/PR negative/HER-2 neu negative tumors. 2014 ASCO Breast Cancer Symposium, 9/2014.
16. Elsayegh N, Lin HY, Gutierrez-Barrera AM, Profato J, Litton JK, Kuerer HM, Hortobagyi GN, Arun B; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center, HOUSTON, TX. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who tested negative for a BRCA mutation. 2014 Breast Cancer Symposium, 9/2014.
17. Schneble EJ, Perez SA, Murray JL, Berry JS, Trappey AF, Vreeland TJ, Hale DF, Greene JM, Clifton GT, Ardavanis A, Litton JK, Ponniah S, Shumway NM, Papamichail M, Peoples GE, Mittendorf EA; San Antonio Military Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece; The University of Texas MD Anderson Cancer Center, Houston, TX; Saint Savvas Anticancer Hospital, Athens, Greece; Cancer Vaccine Development Program, United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, Athens, Greece; San Antonio Military Medical Center, Fort Sam Houston, TX. Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients. 2014 Breast Cancer Symposium, 9/2014.
18. Schneble EJ, Perez SA, Murray JL, Berry JS, Trappey AF, Vreeland TJ, Hale DF, Greene JM, Clifton GT, Ardavanis A, Litton JK, Ponniah S, Shumway NM, Papamichail M, Peoples GE, Mittendorf EA; San Antonio Military Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece; The University of Texas MD Anderson Cancer Center, Houston, TX; Saint Savvas Anticancer Hospital, Athens, Greece; Cancer Vaccine Development Program, United States Military Cancer Institute, USUHS, Bethesda, MD; Cancer Immunology and Immunotherapy Center, Athens, Greece; San Antonio Military Medical Center, Fort Sam Houston, TX. Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients. 2014 Breast Cancer Symposium, 9/2014.
19. Dalal S, Hui D, Yeung SJ, Chisholm GB, Ihenacho IS, Ogunti R, De la Cruz M, Vidal M, Bedi D, Dev R, Bruera E, Litton JK: The University of Texas MD Anderson Cancer Center, Houston, TX. Association between visceral adiposity, BMI, and clinical outcomes in postmenopausal women with operable breast cancer. 2014 ASCO Annual Meeting (#513), 5/2014.
20. Mitri ZI, Jackson M, Garby C, Giordano SH, Hortobagyi GN, Singletary C, Hashmi SS, Arun B, Litton JK; The University of Texas MD Anderson Cancer Center, Houston, TX; Baylor Health, Dallas, TX; The University of Texas Health and Science Center at Houston, Houston, TX. BRCAPRO 6.0 model validation in male patients presenting for BRCA testing. 2014 ASCO Annual Meeting (#1559), 5/2014.
21. Murthy RK, Chen H, Wei S, Jackson M, Woodson AH, Litton JK, Arun B, Valero V, Barcenas CH; The University of Texas MD Anderson Cancer Center, Houston, TX. Genetic testing referral patterns and clinical outcomes among high-risk breast cancer survivors. 2014 ASCO Annual Meeting (#9589), 5/2014.
22. Rugo HS, Chambers MS, Litton JK, Mayer IA, Rogerio JW, DeMars LR, Geronimo J, Warsi G, Meiller TF; University of California San Francisco Medical Center, San Francisco, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Vanderbilt University, School of Medicine, Nashville, TN; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Greenebaum Cancer Center, University of Maryland, Baltimore, MD. Prevention of stomatitis in patients with hormone receptor–positive advanced breast cancer treated with everolimus plus exemestane: A phase II study of a steroid-based mouthwash. 2014 ASCO Annual Meeting (#TPS661), 5/2014.
23. Kogawa T, Fouad TM, Wei C, El-Zein RA, Masuda H, Chavez-Mac-Gregor M, Melhem-Bertrandt A, Litton JK, Brewster AM, Alvarez RH, Hortobagyi GN, Vicente V, Ueno NT, Theriault RL. The University of Texas MD Anderson Cancer Center, Houston, TX. Association between body mass index change during neoadjuvant chemotherapy and pathologic complete response and overall survival in patients with inflammatory breast cancer or locally advanced non-inflammatory breast cancer. 2013 CTRC-AACR San Antonio Breast Cancer Symposium (#PD2-4), 12/2013.
24. Kelly CM, Beamish R, McCaffrey J, Smith M, Crown J, O'Connor M, McGee SF, O'Reilly S, Moylan EJ, Gonzalez-Angulo AM, Litton JK, Pusztai L, Kelly CM; Department of Medical Oncology, Cork University Hospital, Cork, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Department of Medical Oncology, Mater Misericordiae University Hospital, Dublin, Ireland; Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland; Waterford Regional Hospital, Waterford, Ireland; The University of Texas MD Anderson Cancer Center, Houston, TX; Yale Cancer Center, New Haven, CT. A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer. 2013 ASCO Annual Meeting (#598), 5/2013.
25. Campone M, Lebrun F, Noguchi S, Pritchard KI, Burris HA, Beck JT, Ito Y, Yardley DA, Bachelot TD, Pistilli B, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Litton JK, Panneerselvam A, El-Hashimy M, Taran T, Gnant M; CLCC René Gauducheau, Centre de Recherche en Cancerologie, Nantes Saint Herblain, France; Jules Bordet Institute, Brussels, Belgium; Department of Breast and Endocrine Surgery, Osaka University, Osaka, Japan; Odette Cancer Centre, Sunnybrook Health Sciences Centre; University of Toronto, Toronto, ON, Canada; Sarah Cannon Research Institute, Nashville, TN; Highlands Oncology Group, Fayetteville, AR; Cancer Institute Hospital, Japanese Foundation for Cancer Research Breast Medical Oncology, Breast Oncology Center, Tokyo, Japan; Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN; Centre Léon Bérard, Lyon, France; Ospedale di Macerata, Macerata, Italy; Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Arena Oncology Associates, Lake Success, NY; Orbis Medical Center, Sittard, Netherlands; Horizon Oncology Research, Lafayette, IN; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Pharmaceuticals Corp, Florham Park, NJ; Novartis Pharmaceuticals Corp, East Hanover, NJ; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2. 2013 ASCO Annual Meeting (#506), 5/2013.
26. Afrough A, Lin H, Gutierrez-Barrera AM, Litton JK, Valero V, Arun B; The University of Texas MD Anderson Cancer Center, Houston, TX. Outcomes of HER2-positive nonmetastatic breast cancer patients with or without deleterious BRCA mutations after trastuzumab treatment. 2013 ASCO Annual Meeting (#1500), 5/2013.
27. Patil R, Clifton GT, Litton JK, Shumway NM, Vreeland TJ, Berry JS, Trappey AF, Ponniah S, Peoples GE, Mittendorf EA; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY; Blanchfield Army Community Hospital, Fort Campbell, KY; The University of Texas MD Anderson Cancer Center, Houston, TX; San Antonio Military Medical Center, Fort Sam Houston, TX; Brooke Army Medical Center, San Antonio, TX; Cancer Vaccine Development Program, United States Military Cancer Institute, USUHS, Bethesda, MD; Department of Surgery, Brooke Army Medical Center, Fort Sam Houston, TX. Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting. 2013 ASCO Annual Meeting (#3096), 5/2013.
28. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-MacGregor M; University of Texas M. D. Anderson Cancer Center, Houston, TX. ACE inhibitors and angiotensin receptor blockers use and breast cancer outcomes in patients treated with neoadjuvant systemic chemotherapy. 2012 ASCO Annual Meeting (#537), 6/2012.
29. Yennurajalingam S, Frisbee-Hume S, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Palmer JL, Reddy AS, Hui D, Dalal S, Massie L, Vadhan-Raj S, Reddy SK, Reuben JM, Bruera E; University of Texas M. D. Anderson Cancer Center, Houston, TX; Four Seasons Hospice, Flat Rock, NC. Dexamethasone (DM) for cancer-related fatigue: A double-blinded, randomized, placebo-controlled trial. 2012 ASCO Annual Meeting (#9002), 6/2012.
30. Dallas NA, Yi M, Hunt K, Shah RR, Kuerer HM, Litton JK, Wu Y, Caudle AS, Meric-Bernstam F, Sahin AA, Mittendorf EA; University of Texas M. D. Anderson Cancer Center, Houston, TX. Evaluation of the stage IB designation of the 7th edition of the AJCC staging system. 2012 ASCO Annual Meeting (#1130), 6/2012.
31. Dawood SS, Dent RA, Gupta S, Litton JK, Mustafa R, Cortes J, Mittendorf EA, Gonzalez-Angulo AM, Buchholz TA; Dubai Hospital, Dubai, United Arab Emirates; National Cancer Centre Singapore, Singapore, Singapore; Tata Memorial Hospital, Mumbai, India; University of Texas M. D. Anderson Cancer Center, Houston, TX; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain. Impact of surgery and radiation of the primary among women with de novo stage IV breast cancer. 2012 ASCO Annual Meeting (#1032), 6/2012.
32. Elsayegh N, Gutierrez-Barrera AM, Muse KI, Lin H, Turco DL, Litton JK, Kuerer HM, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX. Predictors of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ (DCIS) who underwent evaluation for BRCA genetic testing. 2012 ASCO Annual Meeting (#1549), 6/2012.
33. Milbourne A, Sun CC, Fanale MA, Theriault RL, Rimes SA, Litton JK, Ramirez MM; University of Texas M. D. Anderson Cancer Center, Houston, TX; Baylor School of Medicine, Houston, TX. Pregnancy outcomes in women with cancer. 2012 ASCO Annual Meeting (#6116), 6/2012.
34. Litton JK, Etzel CJ, Jackson MA, Muse KI, Turco D, Schover LR, Theriault RL, Mattair D, Lu KH, Hortobagyi GN, Arun BK. Breast cancer, BRCA mutations and attitudes regarding pregnancy and preimplantation genetic diagnosis. 2011 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2011.
35. Muse KI, Elsayegh N. Gutierrez-Barrera AM, Kuerer H, Valero V, Litton JK, Hortobagyi GN, Arun BK. Evaluation of BRCAPro Risk assessment model in patients with ductal carcinoma in situ. 2011 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2011.
36. Turco DL, Elsayegh N, Litton JK Hortobagyi GN, Arun B. Testing women with invasive lobular breast cancer for BRCA mutations. 2011 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2011.
37. Arun B, Biswas S, Tankhiwale N, Blackford AL, Gutierrez-Barrera AM, Litton JK, Hortobagyi GN, Amos CI, Parmigiani G; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of North Texas Health Science Center, Fort Worth, TX; The Johns Hopkins University School of Medicine, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA. Assessing the added value of breast tumor markers in breast cancer genetic risk prediction model BRCAPRO. 2011 ASCO Breast Cancer Symposium (#164), 9/2011.
38. Jackson M, Mattair D, Lin H, Gutierrez-Barrera AM, Elsayegh N, Litton JK, Hortobagyi GN, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX. Identifying genomic rearrangements in BRCA1 and BRCA2 in high-risk individuals for hereditary breast and ovarian cancer. 2011 ASCO Breast Cancer Symposium (#163), 9/2011.
39. Holland MG, McCampbell A, Litton JK, Theriault RL, Ramirez MM; University of Texas Health Science Center at Houston, Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX. Alterations in breast cancer resistance protein in human placentas exposed to chemotherapy. 2011 ASCO Annual Meeting (#1106), 6/2011.
40. Dawood SS, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM; Dubai Hospital, Dubai, United Arab Emirates; University of Texas M. D. Anderson Cancer Center, Houston, TX; M. D. Anderson Cancer Center, Houston, TX. Effect of body mass index on survival outcome among women with early-stage, triple-negative breast cancer. 2011 ASCO Annual Meeting, 6/2011.
41. Lei X, Dawood SS, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM; University of Texas M. D. Anderson Cancer Center, Houston, TX; Dubai Hospital, Dubai, United Arab Emirates; M. D. Anderson Cancer Center, Houston, TX. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. 2011 ASCO Annual Meeting (#1039), 6/2011.
42. Morrow PK, Broxson AC, Munsell M, Basen-Engquist K, Rosenblum CK, Nguyen LH, Schover LR, Hahn K, Litton JK, Hortobagyi GN; University of Texas M. D. Anderson Cancer Center, Houston, TX. Long-term effects of the diagnosis and treatment of breast cancer upon young breast cancer survivors. 2011 ASCO Annual Meeting (#9045), 6/2011.
43. Gonzalez-Angulo AM, Green MC, Murray JL, Palla SL, Koenig KH, Brewster AM, Valero V, Ibrahim NK, Moulder SL, Litton JK, Crawford DJ, Flores PR, Dryden MJ, Symmans WF, Giordano SH, Pusztai L, Buzdar A, Mills GB, Hortobagyi GN, Meric-Bernstam F; M. D. Anderson Cancer Center, Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas M. D. Anderson Cancer Center, Houston, TX. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). 2011 ASCO Annual Meeting (#1016), 6/2011.
44. Litton JK, Hodge S, Mattair D, Ramirez MM, Morrow PK, Gonzalez-Angulo AM, Barnett CM, Hortobagyi GN, Theriault RL. Outcomes of children exposed to chemotherapy in utero for breast cancer. 2011 ASCO Annual Meeting (#1099), 6/2011.
45. Chavez-MacGregor M, Lei X, Litton JK, Melhem A, Mittendorf EA, Meric-Bernstam F, Sahin AA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM; University of Texas M. D. Anderson Cancer Center, Houston, TX; M. D. Anderson Cancer Center, Houston, TX. Predictors of recurrence among patients with breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant systemic chemotherapy. 2011 ASCO Annual Meeting (#1036), 6/2011.
46. Elsayegh N, Bayraktar S, Gutierrez-Barrera AM, Lin H, Kuerer HM, Muse KI, Ready K, Litton JK, Meric-Bernstam F, Hortobagyi GN, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX; Jackson Memorial Hospital, University of Miami, Miami, FL. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. 2011 ASCO Annual Meeting (#1512), 6/2011.
47. Chavez-MacGregor M, Brown EN, Lei X, Hsu L, Meric-Bernstam F, Litton JK, Mittendorf EA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. 2010 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2010.
48. Melhem-Bertrandt A, Reddy KJ, Gutierrez-Barrera AM, Litton JK, Strong LC, Olopade OI, Hortobagyi GN, Arun BK. Increased rate of HER2-positive breast cancers among women with germline TP53 mutations. 2010 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2010.
49. Arun BK, Gutierrez-Barrera AM, Akar U, Litton JK, Albarracin C, Gonzalez-Angulo AM, Hortobagyi GN. Outcome of triple negative breast cancer in patients with or without deleterious BRCA mutations. 2010 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2010.
50. Pusztai L, Moulder S, Litton JK, Valero V, Ueno N, Melhem-Bertrandt A, Morrow PK, Dotter K, Mattair D, Strauss L, Hortobagyi GN, Qi Y, Symmans WF. Prospective testing of three different gene-signatures for patient selection for dasatinib therapy in metastatic breast cancer. 2010 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2010.
51. Chen JQ, Litton JK, Ziao L, Zhang H-Z, Warneke CL, Wu Y, Shen X, Sahin A, Katz R, Murray JL, Radvanyi L. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. 2010 CTRC-AACR San Antonio Breast Cancer Symposium, 12/2010.
52. Gutierrez-Barrera AM, Turco DL, Alvarez RH, Litton JK, Valero V, Hortobagyi GN, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX. BRCA mutations in women with inflammatory breast cancer. 2010 ASCO Breast Cancer Symposium (#192), 10/2010.
53. Litton JK, Warneke CL, Hahn K, Palla SL, Kuerer HM, Perkins GH, Middleton LP, Gonzalez-Angulo AM, Hortobagyi GN, Theriault RL. Case-control analysis of patients (pts) treated with chemotherapy during pregnancy for breast cancer (BC). 2010 ASCO Breast Cancer Symposium (#105), 10/2010.
54. Litton JK, Warneke CL, Hahn KM, Palla SL, Kuerer HM, Perkins GH, Middleton LP, Gonzalez-Angulo AM, Hortobagyi GN, Theriault RL. Case-control analysis of patients treated with chemotherapy during pregnancy for breast cancer. 2010 ASCO Breast Cancer Symposium, 10/2010.
55. Gonzalez-Angulo AM, Chen H, Timms K, Litton JK, Potter J, Lanchbury JS, Arun B, Hortobagyi GN, Do K, Meric-Bernstam F; University of Texas M. D. Anderson Cancer Center, Houston, TX; Myriad Genetics, Inc., Salt Lake City, UT. Incidence and outcome of BRCA mutation carriers with triple receptor-negative breast cancer (TNBC). 2010 ASCO Breast Cancer Symposium (#160), 10/2010.
56. Ready K, Gutierrez-Barrera AM, Litton JK, Lu KH, Hortobagyi GN, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX. Obesity, smoking, alcohol consumption, and risk of multiple primary breast cancers in BRCA1 and BRCA2 mutation carriers. 2010 ASCO Breast Cancer Symposium (#191), 10/2010.
57. Jackson M, Brandt A, Gutierrez-Barrera A, Meric-Bernstam F, Litton JK, Lu KH, Hortobagyi GN, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX. Effects of ethnicity on genotype-phenotype correlations in individuals with a BRCA1 or BRCA2 mutation. 2010 ASCO Annual Meeting (#6060), 6/2010.
58. Pusztai L, Moulder SL, Litton JK, Valero V, Ueno NT, Morrow PH, Dotter K, Mattair D, Strauss LC, Symmans WF; University of Texas M. D. Anderson Cancer Center, Houston, TX; Bristol-Myers Squibb, Wallingford, CT. Gene-signature-based patient selection for dasatinib therapy in metastatic breast cancer (MBC). 2010 ASCO Annual Meeting (#TPS130), 6/2010.
59. Meric-Bernstam F, Gutierrez-Barrera A, Litton JK, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun B; University of Texas M. D. Anderson Cancer Center, Houston, TX. Mutation position in BRCA-associated breast cancers. 2010 ASCO Annual Meeting (#1542), 6/2010.
60. Litton JK, Chen H, Mittendorf EA, Meric-Bernstam F, Chavez-MacGregor M, Woodward WA, Sahin A, Theriault RL, Hortobagyi GN, Gonzalez-Angulo AM. Outcomes differences in tumors < 1cm by age and breast cancer subtype. 2010 ASCO Annual Meeting (#580), 6/2010.
61. Chavez-MacGregor M, Hubbard R, Meric-Bernstam F, Shinde SS, Litton JK, Woodward WA, Valero V, Hortobagyi GN, Symmans WF, Gonzalez-Angulo AM; University of Texas M. D. Anderson Cancer Center, Houston, TX; Division of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Illinois at Urbana-Champaign, Urbana, IL. Residual cancer burden (RCB) in breast cancer patients treated with taxane- and anthracycline-based neoadjuvant chemotherapy: The effect of race. 2010 ASCO Annual Meeting (#607), 6/2010.
62. Guarneri V, Chavez-MacGregor M, Hsu L, Symmans WF, J. K. Litton, Mittendorf EA, Conte PF, Hortobagyi GN, Gonzalez-Angulo AM; Department of Oncology, Hematology, and Respiratory Diseases, Modena University Hospital, Modena, Italy; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Oncology and Hematology, University Hospital, Modena, Italy. Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. 2010 ASCO Annual Meeting (#621), 6/2010.
63. Yu TK, Tereffe W, Bedrosian I, Eskambi SH, Strom EA, Litton JK, Gonzalez-Angulo AM, Buchholz TA, Hunt KK, Mittendorf EA; M. D. Anderson Cancer Center, Houston, TX. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. 2009 CTRC-AACR San Antonio Breast Cancer Symposium (#957), 12/2009.
64. Litton JK, Ready K, Gutierrez-Barrera A. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. 2009 ASCO Breast Cancer Symposium (#7), 9/2009.
65. Chavez-MacGregor M, Litton JK, Huiquin C, Meric-Bernstam F, Hudis CA, Wolff A, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM; University of Texas, M. D. Anderson Cancer Center, Houston, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. Race and pathologic complete response (pCR) in breast cancer patients receiving anthracycline and taxane-based neoadjuvant chemotherapy. 2009 ASCO Breast Cancer Symposium (#229), 8/2009.
66. Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin A, Le-Petross H, Oh J, Litton JK, Hwang RF, Mittendorf EA; M. D. Anderson Cancer Center, Houston, TX. Clinicopathologic factors associated with involved margins following breast conserving surgery for invasive lobular carcinoma (ILC). 2009 ASCO Annual Meeting (#e11528), 6/2009.
67. Ready, Gutierrez-Barrera AM, Litton JK, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun B. Racial differences in the use of contralateral prophylactic mastectomy among women undergoing BRCA1/BRCA2 genetic testing. 2009 ASCO Annual Meeting (#6542), 1/2009.
68. Arun B, Atchley D, Litton JK, Pusztai L, Valero V, Hortobagyi GN, Albarracin CT. Response to neoadjuvant chemotherapy in BRCA1- and BRCA2-related breast cancers. 2008 ASCO Annual Meeting (#618), 2008.
69. Rakkhit R, Broglio K, Peintinger F, Cardoso F, Hanrahan E, Litton J, Sahin A, Larsimont D, Meric-Bernstam F, Buchholz T, Valero V, Theriault R, Piccart M, Hortobagyi GN, Ravdin P, Gonzalez-Angulo AM. Significant increased recurrence rates among breast cancer patients with HER2-positiveT1abN0M0 tumors. 2008 CTRC-AACR San Antonio Breast Cancer Symposium, 2008.
70. Litton JK, Chen JQ, Warneke C, Zhang HZ, Berenstein N, Sahin A, Bondy ML, Hortobagyi GN, Murray JL, Radvany L. TRPS-1 in breast cancer. 2008 CTRC-AACR San Antonio Breast Cancer Symposium (#50), 2008.
71. Litton JK, Gonzalez-Angulo AM, Warkene CL, Kau SW, Buzdar AU, Bondy M, Mahabir S, Hortobagyi GN, Brewster A. Body mass index and response to neoadjuvant chemotherapy. 2007 ASCO Annual Meeting (#531), 2007.
72. Litton JK, Westin KN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Bodurka DC, Lu KH, Hortobagyi GN, Arun BA. Perception of screening and risk-reduction surgeries in patients tested for a BRCA mutation. 2007 CTRC-AACR San Antonio Breast Cancer Symposium (#5), 2007.

Letters to the Editor

1. Litton JK, Lee JH, Arun BK. Reply to BRCA2-Associated Pancreatic Cancer and Current Screening Guidlines. Cancer 121(17):3047, 9/2015.
2. Theriault RL, Litton JK. Reply to d. Crivellari et A. J Clin Oncol 32(3):256-7, 2014. PMID: 24297948.

Grant & Contract Support

Title: Combining Targeting of Chk1 and PARP to Triple Negative Breast Cancer
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Collaborator
Principal Investigator: Dr. Helen Piwnica-Worms
Duration: 7/1/2012 - 6/30/2016
 
Title: Attitudes About Childbearing and Fertility in Women Seeking Genetic Testing for Inherited Breast and Ovarian Cancer Syndrome (HBOC)
Funding Source: Texas Business Women
Role: Investigator
Duration: 9/2010 - 9/2011
 
Title: Increasing Primary Care Provider's Competence for Identifying and Managing Persons at Increased Breast Cancer Risk: A Professional Oncology Prevention Program
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Collaborator
Principal Investigator: Arun, Banu
Duration: 6/2010 - present
 
Funding Source: Wolff-Toomin Philanthropic gift for Breast Cancer Research
Role: Principal Investigator
Duration: 3/2010 - 3/2015

Last updated: 8/21/2015